<DOC>
	<DOCNO>NCT00801697</DOCNO>
	<brief_summary>This study evaluate safety preliminary immune response recombinant adenoviral serotype 35 5 HIV-1 vaccine HIV-uninfected adult .</brief_summary>
	<brief_title>Safety Immune Response Preventive HIV Immunization With Adenovirus Serotype 5 35 Vector</brief_title>
	<detailed_description>One promising approach development preventive HIV vaccine use DNA plasmid prime immune response adenoviral vector boost . This primary purpose study evaluate safety , tolerability , immune response recombinant adenoviral serotype 35 ( rAd35 ) serotype 5 ( rAD5 ) HIV-1 vaccine Ad-5 naive Ad-5 expose HIV-uninfected adult . This study last approximately 12 month . Participants include rAD5-naive rAD5-exposed stratify one four group . Each group consist two arm , one interventional one control . Participants Groups 1 , 2 , 3 rAD5-naive . Participants Group 4 rAD5-exposed . Participants Group 1 receive injection rAD35 vaccine placebo study entry injection rAD5 vaccine placebo Month 6 nine follow-up visit Month 12 . Participants Groups 2 , 3 , 4 injection DNA vaccination placebo study entry Months 1 2 , injection rAD35 vaccine , rAD5 vaccine , placebo Month 6 twelve follow-up visit though Month 12 . A physical , questionnaire , counsel occur visit . Blood urine collection occur visit . A rectal swab occur select visit . For female , pregnancy test occur visit . Participants contact safety follow-ups injection every year 5 year . Health adverse event record . Participants need return study clinic unless HIV confirmatory test need .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good general health Access participate HVTN clinical research site willingness follow duration study Assessment understanding , include understanding Step Study result Willing receive HIV test result Willing discuss HIV infection risk , agree HIV risk reduction counseling , willing continue 5 year annual followup contact Willing commit maintain behavior consistent low risk HIV exposure last require protocol visit Considered low risk HIV infection clinical staff assessment . More information criterion find protocol . Certain laboratory value . More information criterion find protocol . Negative Hepatitis B surface antigen Negative antiHepatitis C virus antibody For female , agree use effective contraception least 21 day prior enrollment last protocol visit . More information criterion find protocol . HIVinfected Active drug alcohol abuse within 12 month prior study entry History newly acquire sexually transmit infection . More information criterion find protocol . Experimental vaccine receive within 5 year prior study entry Immunosuppressive medication receive within 168 day prior first vaccination Blood product receive within 120 day prior first vaccination Immunoglobulin receive within 60 day prior first vaccination Live attenuate vaccine receive within 30 day prior first vaccination Investigational research agent receive within 30 day prior first vaccination Intent participate another study investigational research agent plan duration study Any vaccine live attenuate vaccine receive within 14 day prior first vaccination Allergy treatment antigen injection within 30 day prior first vaccination schedule within 14 day first vaccination Clinically significant medical condition , finding , result , history implication current health . More information criterion find protocol . Serious adverse reaction vaccine Autoimmune disease Immunodeficiency Active Syphilis infection within past 6 month Asthma . More information criterion find protocol . Diabetes mellitus Thyroidectomy thyroid disease require medication last 12 month Hypertension . More information criterion find protocol . Body mass index great 35 40 . More information criterion find protocol . Bleeding disorder Malignancy Seizure disorder Asplenia Psychiatric condition precludes compliance protocol Any clinically significant condition laboratory abnormality , opinion investigator , would interfere study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>Adenovirus</keyword>
</DOC>